InSpire MD to Announce Six-Month Results From The MGuard™ Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

Published: May 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ –

InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a robust schedule of educational events and data presentations at EuroPCR, culminating in the first presentation of 6-month results from the MASTER (MGuardfor Acute STElevation Reperfusion) trial of the Company’s MGuard™ Embolic Protection Stent (EPS).

Help employers find you! Check out all the jobs and post your resume.

Back to news